Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sentrx, a provider of drug safety services to the life science industry, is launching CROplus, a comprehensive channel partner solution for CROs. The solution was first discussed at the 19th Annual Partnerships in Clinical Trials Conference in Orlando, FL.
Subscribe to our email newsletter
Sentrx claimed that CROplus addresses four critical areas such as custom adverse event management, high speed drug safety implementation, embedded safety technology expertise and flexible client management reporting, CROs targeted in a PV channel partner.
Charles Saldarini, CEO of Sentrx, said: “Sentrx received excellent feedback at Partnerships. It is clear the needs sponsor organisations have to seamlessly integrate pharmacovigilance with clinical development is producing new opportunities for CROs.
“Our channel partner solution provides an easy to use set of PV capabilities, knowledge and expertise for CROs.”
Michael Gorman, chief financial officer and vice president for Strategic Alliances, said: “Sentrx CROplus is an enabling solution to connect CROs to the $2bn PV market.
“Our commercial solutions team is ready to help CROs develop proposals, assess ROI and establish road maps for additional safety services we are developing internally and with our business partners Oracle and Phase Forward.”